Search Results 271-280 of 15109 for TNF

  1. Publications - Dan P. Larson, M.D. - Mayo Clinic

    Disseminated histoplasmosis and hemophagocytic lymphohistiocytosis in a patient receiving TNF-alpha inhibitor therapy. IDCases. 2022; 29:e01603. Epub 2022 ...

  2. Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer - Mayo Clinic

    anti-TNF alpha agents) =< 2 weeks prior to randomization, or anticipation of need for systemic immunosuppressive medication during study treatment, with the ...

  3. Publications - Clement J. Michet, Jr., M.D. - Mayo Clinic

    ... Tumor Necrosis Factor ... 2012 Mar; 18: (2)92-5. View PubMed; Raja H, Matteson EL, Michet CJ, Smith JR, Pulido JS. Safety of Tumor Necrosis Factor Inhibitors ...

  4. A Study to Assess the Effectiveness and Safety of Apremilast in Pediatric Patients (6 through 17 years old) with Moderate-to-Severe Plaque Psoriasis - Mayo Clinic

    Other TNF or IL-17 blockers (such as infliximab, certolizumab pegol, secukinumab, ixekizumab, brodalumab, or their biosimilars) within 12 weeks prior to ...

  5. Publications

    Publications. Shanafelt TD, West CP, Sinsky C, Trockel M, Tutty M, Wang H, Carlasare LE, Dyrbye LN. Changes in Burnout and Satisfaction With Work-Life ...

  6. Home Care Treatment With Oral Chemotherapy For Recurrent Or Metastatic Oral Cavity Cancer - Mayo Clinic

    About this study. The purpose of this study is to demonstrate feasibility of conducting a decentralized therapeutic clinical trial of triple oral metronomic ...

  7. A Study of Taxane, Trastuzumab, and Pertuzumab With or Without Atezolizumab in Treating Metastatic Breast Cancer Patients - Mayo Clinic

    ... TNF] factor agents) within 14 days prior to randomization or anticipation of need for systemic immunosuppressive medications during the study. Note ...

  8. Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome - Mayo Clinic

    methotrexate, azathioprine, anti-tumor necrosis factor (TNF) agents, etc. with the exception of steroids - Administration of a live or live attenuated ...

  9. A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF) - Mayo Clinic

    ... (TNF- a) inhibitors. * Medications that are under investigation for the treatment of IPF including inhaled treprostinil and Phosphodiesterase-4 (PDE-4) ...

  10. Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis - Mayo Clinic

    ... TNF agents, and rituximab). Subjects with an MMT-8 score ≤ 66 (see Appendix B) must also have at least 2 other core set measures meeting the criteria ...